Content by The Scientist

A Region Defined The Greater Philadelphia life science cluster is a powerhouse of human capital spread across a wide network of big pharmaceutical companies, research-intensive institutions, top-notch academia, emerging biotech giants, and a strong infrastructure of support services. This section highlights each component of the network, the region's commitment to commercialization, and the challenges its leaders are working hard to resolve. A Region Defined Did

Navigating the Network RELATED ARTICLES Growth and Development A Region Poised for (More) Growth Big-City Excitement Meets Country Charm Where Do We Go from Here? The Greater Philadelphia region is well-known for its rich asset base. Through the end of 2004, this base included 54,500 people employed in the core life sciences and 327,000 employed in related sectors. With more than 400 companies in the region related to life science, finding your n

Select Greater Philadelphia If you're a biotech professional standing where this country declared its independence (Philadelphia, that is) you would also be in the center of a major life science community. You could literally walk in any direction and come across pillars of the life science community like Novo Nordisk in southern New Jersey, AstraZeneca in northern Delaware, GlaxoSmithKline in downtown Philadelphia and Cephalon in the suburbs of southeastern Penn

Growth and Development Although the life sciences employ at least 11.4% of the total working population of Greater Philadelphia, there's room for more business to join this network of professionals. The area's business leaders are preparing for more growth as well as for ways people can stay connected and find future partners. A Region Poised for (More) Growth Big-City Excitement Meets Country Charm Navigating the Network Where Do We Go from Here?

This month, researchers decided to play around with a particular protein structure

Tell us what you think about the agency's ideas for improving how it evaluates grant applications

View the results of the first ever Laboratory Web Site and Video Awards

The EtiologyARTICLE EXTRASMolecular MysteriesGazing DownstreamSeeing SchizophreniaNeurotrailblazerPregnancy, Chromosomes, and ReceptorsAlthough science has made significant strides in the understanding of schizophrenia, in many ways its causes remain as mysterious today as they were when Eugen Bleuler coined the term in 1905. As Melinda Wenner describes in this section, the dopamine hypothesis that gave rise to a generation of antipsychotics has been forced to share the stage with a host of othe

The Disease ARTICLE EXTRAS Living with Schizophrenia Robin Cunningham Marianne Emanuel A Very Expensive Disease Schizophrenia in Childhood This year, some 600,000 people will be diagnosed with schizophrenia. That's 600,000 lives - and many times that when you consider their families - thrown into what some have described as a living hell. People with the disease are far more likely to be jobless, ill with other diseases, and commit suicide. So it is approp

The Treatments ARTICLE EXTRAS A Troubled History First-Generation Antipsychotic Drugs The Atypical Atypical? The next generation? The Lessons of CATIE Second-Generation Antipsychotic Drugs Beyond Drugs Nonmedication Therapies When you add up the direct costs of treating patients with schizophrenia, it is a staggering number: $22 billion in the United States alone. As effective as many of them are, antipsychotic drugs are costly, and many have signific

A Troubled History Antipsychotics are effective, but carry significant side effects and cost. What's on the horizon? ARTICLE EXTRAS The Treatments First-Generation Antipsychotic Drugs The Atypical Atypical? The next generation? The Lessons of CATIE Second-Generation Antipsychotic Drugs Beyond Drugs Nonmedication Therapies Soon after antipsychotics entered the market in the 1950s, policymakers were so impressed with their benefits th

The next generation? ARTICLE EXTRAS The Treatments A Troubled History First-Generation Antipsychotic Drugs The Atypical Atypical? The Lessons of CATIE Second-Generation Antipsychotic Drugs Beyond Drugs Nonmedication Therapies This table lists a selection of antipsychotics in the pipeline. For a story on a new class of drugs some are referring to as the "atypical atypicals," click here. For a table of first-generation drugs, click here. For a table of a

Second-Generation Antipsychotic Drugs This table lists the atypical antipsychotics. For a story on the lessons of the CATIE trial, click here. For a table of first-generation drugs, click here. For a table of drugs in the pipeline, click here. Drug Brand name(Manufacturer) Approval date Indications Mechanism Cost per 30-day supply* Contraindications/Adverse reactions Injection availability Other data Clozapine Clozaril (N

Hurry up and submit you vote for The Scientist's Laboratory Web Site and Video Awards - voting ends Tuesday, December 4

Survey closes end of November, so respond today! Your voice could make the difference in your institution's place in the ranking.